Thrombopoietin Receptor

血小板生成素 (TPO) 是巨核细胞生成和血小板形成的主要调节剂。c-mpl 基因编码的蛋白质 CD110 是一个 635 个氨基酸的跨膜结构域,具有两个细胞外细胞因子受体结构域和两个细胞内细胞因子受体盒基序。血小板生成素结合后,CD110 二聚化,非受体酪氨酸激酶 JAK 家族以及 STAT 家族、MAPK 家族、衔接蛋白 Shc 和受体本身被酪氨酸磷酸化。

TPO 与血小板、巨核细胞和多能干细胞上的血小板生成素受体 (TPOr,也称为 c-mpl) 结合,从而抑制干细胞和巨核细胞的凋亡;增加巨核细胞的数量、大小和倍性;巨核细胞成熟率和血小板计数增加;血小板被 ADP 和胶原蛋白激活的阈值降低。

Thrombopoietin (TPO) is the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.

TPO binds to the thrombopoietin receptor (TPOr, also termed c-mpl) on platelets, megakaryocytes, and pluripotent stem cells leading to inhibition of apoptosis of stem cells and megakaryocytes; increased megakaryocyte number, size, and ploidy; increased rate of megakaryocyte maturation and platelet count; and decreased platelet threshold for activation by ADP and collagen.

共 1种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
MF266-1

MF266-1 是一种选择性 E 前列腺素受体 1 (EP1) 拮抗剂,Ki 值为 3.8 nM,对血小板激活因子 A2 受体 (TP) 也具有中等选择性,有望用于关节炎的研究。

848188-18-1
Antagonist
MF266-1

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础